Allergan and the company’s development partner Sosei Group voluntarily suspended clinical trials of HTL0018318 in Alzheimer’s and other types of dementia because of safety problems.
Allergan Buys Tobira for $1.695 Billion
Alzheimer's Disease, Business, Clinical Trials, DPP-IV Inhibitors, Fibrotic conditions, Health, Immunomodulator Drugs, Inflammation, M&A, Muscarinic receptor agonists, Neurodegenerative Diseases, Non-alcoholic steatohepatitis (NASH), R&D, Shares, U.S. Treasury DepartmentIn yet another buy in its string of acquisitions, Dublin-based Allergan announced it was acquiring San Francisco-based Tobira Therapeutics.
One day after the Pfizer deal to buy Allergan was officially terminated, Allergan announced a multibillion pact with Heptares Therapeutics for neurological disorders.